[Advanced credit: patient enrolling and therapy initiation in the ADVANCE trial]

Abstract

In the new millennium, high blood pressure and diabetes are emerging as one of the greatest threats to the health of populations worldwide. The comanagement of diabetes (hemoglobinA1c < 6.5%), and hypertension (blood pressure <130/80 Hgmm), has become central to the prevention of macro- and microvascular disease in diabetic patients. The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN trial, the first large prospective multicenter randomized controlled trial, uses a factorial 2 x 2 design to determine the effects on macro- and microvascular outcomes of blood pressure lowering (with a perindopril/indapamide combination) and of intensive glucose control using a gliclazide MR based regimen.